D
DNA Script
Transforming how molecular biology translates to human health, personalized medicine, and synthetic biology
About DNA Script
DNA Script revolutionizes DNA synthesis with its proprietary enzymatic technology. The company has developed SYNTAX™️, the world's first benchtop DNA printer, which integrates innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. DNA Script serves clients in genomics research and personalized medicine, providing a cutting-edge tool that simplifies and accelerates DNA synthesis. Operating in the biotechnology market, the company generates revenue through the sale of its SYNTAX™️ system and related consumables. By enabling rapid and efficient DNA synthesis, DNA Script aims to drive advancements in genomics and personalized healthcare.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Le Kremlin-Bicêtre, France
- Employees
- 132
- Open positions
- 5
- Dealroom signal
- 66.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Enzymes, Precision Medicine, Synthetic Biology, Spinout, Genome Engineering
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2022 | $35M | $825M | Irving Investors · Baillie Gifford · T. Rowe Price · EureKARE | ↗ |
| SERIES COther financing | Oct 2021 | $165M | $660M | Farallon Capital Management · EQT Life Sciences · Danaher · Alexandria Venture Investments | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for DNA Script is 6.5K monthly website visits, up 25% over the last three months. DNA Script's team declined 8.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Kurma Partners
Sofinnova Partners
Eurazeo
Bpifrance
European Innovation Council
Series A6 investors entered at this stage
Illumina Ventures
M Ventures
EQT Life Sciences
Casdin Capital
Agilent
Danaher
Series B and later13 investors entered at this stage
Catalio Capital Management
Coatue Management
Farallon Capital Management
Alexandria Venture Investments- APArrowMark Partners
- CIColumbia Threadneedle Investments
Fidelity Investments
Moore Strategic Ventures
Baillie Gifford
T. Rowe Price- IIIrving Investors
EureKARE
HealthCor Management
Other known investors6 additional known investors
Massachusetts Institute of Technology
Paris Biotech Santé
Rockefeller University
Agoranov
Institut Pasteur- IGInstitut Pierre-Gilles de Gennes
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DNA Script on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DNA Script’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.